These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11839513)

  • 1. New promises for schizophrenia therapy.
    Sridhar N
    Drug Discov Today; 2002 Feb; 7(4):215-6. PubMed ID: 11839513
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone.
    Busatto GF; Pilowsky LS; Ell PJ; Costa DC; Verhoeff NP; Kerwin RW
    Br J Psychiatry; 1993 Dec; 163():833-4. PubMed ID: 7508329
    [No Abstract]   [Full Text] [Related]  

  • 3. Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties.
    Heylen SL; Gelders YG
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():180A-181A. PubMed ID: 1379877
    [No Abstract]   [Full Text] [Related]  

  • 4. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for pharmacotherapy of schizophrenia.
    Pickar D
    Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
    [No Abstract]   [Full Text] [Related]  

  • 6. D2 antagonist augmentation in patients with a partial response to atypical antipsychotics.
    Mazeh D; Melamed Y; Weizman A
    Can J Psychiatry; 2004 Apr; 49(4):281-2. PubMed ID: 15147030
    [No Abstract]   [Full Text] [Related]  

  • 7. Iloperidone (Fanapt)--another second-generation antipsychotic.
    Med Lett Drugs Ther; 2010 Feb; 52(1332):13-4; quiz 17. PubMed ID: 20208474
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist.
    Bristow LJ; Kramer MS; Kulagowski J; Patel S; Ragan CI; Seabrook GR
    Trends Pharmacol Sci; 1997 Jun; 18(6):186-8. PubMed ID: 9226994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iloperidone for schizophrenia.
    Rado J; Janicak PG
    Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia: from dopamine to glutamate and back.
    Carlsson ML; Carlsson A; Nilsson M
    Curr Med Chem; 2004 Feb; 11(3):267-77. PubMed ID: 14965231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of risperidone on positive features of schizophrenia.
    McEvoy JP
    J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions.
    Jin GZ; Zhu ZT; Fu Y
    Trends Pharmacol Sci; 2002 Jan; 23(1):4-7. PubMed ID: 11804640
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine and antipsychotic drug action revisited.
    Jones HM; Pilowsky LS
    Br J Psychiatry; 2002 Oct; 181():271-5. PubMed ID: 12356650
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinion: NK3 receptor antagonists: the next generation of antipsychotics?
    Spooren W; Riemer C; Meltzer H
    Nat Rev Drug Discov; 2005 Dec; 4(12):967-75. PubMed ID: 16341062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment resistance in schizophrenia.
    Johnstone EC; Sandler R
    BMJ; 1996 Feb; 312(7027):325-6. PubMed ID: 8611817
    [No Abstract]   [Full Text] [Related]  

  • 20. British Association for Psychopharmacology--2008 Summer Meeting.
    Jenkins TA
    IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.